Exhibit 99.2
CONTACT:
VIVUS, Inc. |
| Trout Group |
Timothy E. Morris |
| Ian Clements (SF) 415-392-3385 |
Chief Financial Officer |
| Brian Korb (NYC) 646-378-2923 |
650-934-5200 |
|
|
FOR IMMEDIATE RELEASE
VIVUS Announces Upcoming Webcasts and Conference Participation
Mountain View, Calif, November 3, 2008 – VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that they will attend and present an overview of the company at the following conferences in November.
Barclays Capital Small & Mid-Cap Healthcare Forum
Barclays Capital, 745 Seventh Avenue, New York
Presenter: Timothy Morris, CFO
Presentation date: Thursday, November 6, 2008
Presentation time: 3:00pm ET
Rodman & Renshaw Annual Global Investor Conference
The Palace Hotel, New York
Presenter: Leland Wilson, President and CEO
Presentation date: Tuesday November 11, 2008
Presentation time: 12:15pm ET
Credit Suisse Healthcare Conference
Arizona Biltmore, Phoenix
Presenter: Leland Wilson, President and CEO
Presentation date: Friday, November 14, 2008
Presentation time: 10:30am MT
Live audio webcasts and 14-day archive of all of the above presentations will be available at http://ir.vivus.com.
About VIVUS
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity, diabetes and sexual health. The pipeline includes: Qnexa™, which is in phase 3 for the treatment of obesity and phase 2 for the treatment of type 2 diabetes; Testosterone MDTS®, for which a phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, for which a phase 2 study has been completed for the treatment of erectile dysfunction (ED). For more information on clinical trials and products, please visit the company’s web site at http://www.vivus.com.
###